NCT05528315已完成1 期
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Safety and tolerability of ABX-002 in healthy subjects as assessed by incidence of treatment-emergent AEs (TEAEs) and SAEs
研究概览
简要总结
The study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single-ascending doses (SAD) and multiple ascending doses (MAD) of ABX-002 in healthy volunteers (HV)
详细描述
The study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single-ascending doses (SAD) and multiple ascending doses (MAD) of ABX-002 in healthy volunteers (HV) to identify repeated dose levels that are safe and well-tolerated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Placebo matches appearance of ABX-002
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •In good health, based on medical history, physical examination (including neurological examination), vital sign measurements, and laboratory safety tests
- •Body mass index (BMI) 18-32 kg/m2 (inclusive)
- •No clinically significant abnormality on ECG
- •Must be a nonsmoker or a social smoker
- •In agreement to eat a protocol-specified meal
- •Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at the time of the Screening Visit and before the first administration of the study drug
- •WOCBP and all male subjects who are sexually active must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment
排除标准
- •History of any illness that, in the opinion of the study Investigator, might confound the results of the study or pose an additional risk to the subject by virtue of their participation in the study
- •Mentally or legally incapacitated, has significant emotional problems
- •Historical risk of suicide or according to the Investigator's clinical judgement, has made a suicide attempt in the previous 6 months, or has a history of deliberate self-harm in the past 6 months
- •History of clinically significant endocrine, psychiatric, gastrointestinal, cardiovascular, peripheral vascular, neurological, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases in medical history or upon physical examination.
- •History of known pre-existing liver disorders (eg, nonalcoholic fatty liver disease) and unstable liver disease History of clinically significant neoplastic disease, with the exception of adequately treated localized or in situ nonmelanoma carcinoma of the skin (ie, basal cell carcinoma) or of the cervix
- •History or evidence of any of the following: myocardial infarction; cardiac valvulopathy; cardiac surgery revascularization (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty); unstable angina; cerebrovascular accident, stroke, or transient ischemic attack; pacemaker; atrial fibrillation, flutter, or nonsustained or sustained ventricular tachycardia (VT); pulmonary arterial hypertension; sick sinus syndrome, second- or third-degree atrioventricular (AV) block; uncontrolled hypertension; congestive heart failure; personal or family history of sudden death or long QT syndrome; unexplained syncope or syncope within the last 3 years regardless of etiology; or history of hypokalemia
- •Mean systolic blood pressure (BP) > 140 mm Hg or mean diastolic BP > 90 mm Hg
- •History of multiple significant allergies and/or severe allergies (eg, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerability to prescription drugs, nonprescription drugs, or food
- •Major surgery or an invasive procedure performed ≤ 3 months prior to the Screening Visit. Has donated or lost 1 unit (approximately 500 mL) of blood ≤ 56 days prior to the Screening Visit or intends to donate blood or blood products during the course of the study
- •Recently received an influenza or Coronavirus Disease 2019 (COVID-19) vaccination < 1 week prior to Day -2 or intends to have an influenza or COVID-19 vaccination during the course of the study
- •Subjects who are pregnant or breastfeeding
- •Personal history of epilepsy or familial history of epilepsy as documented by medical records or by the history provided to the Investigator by the subject
- •History of febrile seizures or seizures related to medication, intoxication, or withdrawal
- •History of cataract of the lens as documented by medical records or by the history provided to the Investigator by the subject
- •History of neurological abnormalities such as brain injury including traumatic injury, perinatal cerebropathy and postnatal brain damage, blood brain barrier abnormality, or cavernous angioma
研究组 & 干预措施
Single dose, ABX-002
Experimental
Single Dose (solution) dose escalating
干预措施: ABX-002 (Drug)
Single dose, ABX-002
Experimental
Single Dose (solution) dose escalating
干预措施: Placebo (Drug)
Multiple dose, ABX-002
Experimental
Multiple Dose (solution) dose escalating
干预措施: ABX-002 (Drug)
Multiple dose, ABX-002
Experimental
Multiple Dose (solution) dose escalating
干预措施: Placebo (Drug)
Formulation Comparison Solution or Capsule
Experimental
ABX-002 Single Dose TBD - Solution ABX-002 Single Dose TBD - Capsule
干预措施: ABX-002 (Drug)
结局指标
主要结局
Safety and tolerability of ABX-002 in healthy subjects as assessed by incidence of treatment-emergent AEs (TEAEs) and SAEs
时间窗: Change from baseline
Safety will be assessed by AEs, laboratory assessments (eg, hematology, coagulation, blood chemistry, THA markers, bone turnover biomarkers, cardiac and muscle markers, SHBG), urinalysis, pregnancy tests, vital signs (supine, orthostatic), analysis of safety ECGs, incidence and duration of selected cardiac rhythms on Holter monitoring, presence of drug-related excessive slowing or EA on EEG, slit lamp examination of the lens for cataract, and physical and neurological examinations
次要结局
- Pharmacokinetics of ABX-002 in health subjects as assessed in healthy subjects as assessed by plasma exposure (AUC0-t, AUC0-inf) determination of the optimal pharmacokinetic dose(Day 1 to Day 5)
- Pharmacokinetics of ABX-002 in healthy subjects as assessed by terminal elimination half life (t1/2) determination of the optimal pharmacokinetic dose(Day 1 to Day 5)
- Pharmacokinetics of ABX-002 in health subjects as assessed by maximum plasma concentration (Cmax) towards determination of the optimal PK dose(Day 1 to Day 5)
- Pharmacokinetics of ABX-002 in health subjects as assessed by time to maximum concentration (Tmax) towards determination of the optimal PK dose(Day 1 to Day 5)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of ACE-2494 in Healthy SubjectsHealthy VolunteersNCT03478319Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA48
已完成
1 期
Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)Diabetes Mellitus, Type 2NCT01223339Merck Sharp & Dohme LLC24
已完成
1 期
Study With Healthy Japanese and Non-Asian Participants With BMS-986231Heart Decompensation, AcuteNCT02932969Bristol-Myers Squibb56
已完成
1 期
Single Ascending Dose Study of ANX105HealthyNCT05288881Annexon, Inc.23
终止
1 期
A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy ParticipantsSchizophrenia, Cerebellar AtaxiaNCT02566759Neurocrine Biosciences110